BioSpace News Archive

GenFleet Therapeutics today announced that it has entered into a clinical trial collaboration and supply agreement with Merck to start a clinical study of the combination therapy of GFH925 with ERBITUX® (cetuximab) as a potential frontline treatment among NSCLC patients harboring KRAS G12C mutation in a multi-center Phase Ib/II trial in Europe.

BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance, informing the company that a patent application covering i.a. the anti-FcγRllB antibodies BI-1206 and BI-1607 will be granted contingent on payment of the issue fee.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Levocarnitine Tablets USP, 330 mg.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nominating and Governance Committee.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.

Jaguar Health, Inc. (NASDAQ:JAGX) and Napo Therapeutics today announced that an update regarding a third-party clinical investigation of crofelemer for pediatric short bowel syndrome (SBS) and congenital diarrheal disorders (CCD) was presented at the World Congress of Gastroenterology, a global GI conference that took place December 12-14, 2023 in Dubai in the United Arab Emirates (UAE).

ValGenesis and Verista have announced a strategic global partnership to deliver precise manufacturing intelligence and validation services for life sciences companies leveraging ValGenesis’ market-leading Validation Lifecycle Management System® and Verista’s expert domain and validation knowledge.

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a business update on its strategic repositioning and key business developments.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (bsAb).